Edward M. Kaye MD - 03 Dec 2024 Form 4/A - Amendment Insider Report for Stoke Therapeutics, Inc. (STOK)

Role
CEO, Director
Signature
/s/ Jonathan Allan, Attorney-in-Fact
Issuer symbol
STOK
Transactions as of
03 Dec 2024
Net transactions value
$0
Form type
4/A - Amendment
Filing time
10 Dec 2024, 18:59:32 UTC
Date Of Original Report
05 Dec 2024
Previous filing
03 Dec 2024
Next filing
10 Dec 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction STOK Common Stock Options Exercise $0 +26,250 +54% $0.000000 74,841 03 Dec 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction STOK Performance Stock Units Award $0 +52,500 $0.000000 52,500 03 Dec 2024 Common Stock 52,500 Direct F1, F2, F3
transaction STOK Performance Stock Units Options Exercise $0 -26,250 -50% $0.000000 26,250 03 Dec 2024 Common Stock 26,250 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each performance stock unit represents a right to receive one share of the Issuer's common stock.
F2 This award represents a grant of restricted stock units upon the achievement of certain performance criteria as certified by the Issuer's compensation committee on the Transaction Date.
F3 Half the award vests on December 3, 2024 and the remainder shall vest on December 3, 2025, subject to the reporting person's continued service to the Issuer on the relevant vesting date.

Remarks:

This Form 4 is being amended to correct the number of performance-based restricted stock units awarded and vested on December 3, 2024 on Table II, and to correct the reporting person's total securities held on Table I accordingly.